270 related articles for article (PubMed ID: 10151839)
1. Getting SMART (submission management and review tracking) drug review in the computer age.
Flieger K
FDA Consum; 1995 Oct; 29(8):6-9. PubMed ID: 10151839
[TBL] [Abstract][Full Text] [Related]
2. The drive to reform the FDA gains momentum.
Gatty B
Hosp Formul; 1995 Mar; 30(3):178, 177. PubMed ID: 10141250
[No Abstract] [Full Text] [Related]
3. FDA and EMEA pool scientific advice.
Katsnelson A
Nat Biotechnol; 2004 Dec; 22(12):1490-1. PubMed ID: 15583642
[No Abstract] [Full Text] [Related]
4. International Conference on Harmonisation; guidance on electronic common technical document specification; availability. Notice.
Food and Drug Administration, HHS
Fed Regist; 2003 Apr; 68(63):16060-1. PubMed ID: 12674113
[TBL] [Abstract][Full Text] [Related]
5. BIO and biogenerics.
Feldbaum CB
Nat Biotechnol; 2005 Jan; 23(1):17; discussion 17. PubMed ID: 15637607
[No Abstract] [Full Text] [Related]
6. What ails the FDA?
Jenny-Avital ER
N Engl J Med; 2005 Jun; 352(24):2554-5. PubMed ID: 15962407
[No Abstract] [Full Text] [Related]
7. FDA embraces risk-management approach.
Fox JL
Nat Biotechnol; 2003 Oct; 21(10):1120-1. PubMed ID: 14520383
[No Abstract] [Full Text] [Related]
8. Biogenerics standoff.
Herrera S
Nat Biotechnol; 2004 Nov; 22(11):1343-6. PubMed ID: 15529145
[No Abstract] [Full Text] [Related]
9. A critical tipping point.
Zuckerman MB
US News World Rep; 2002 Apr; 132(13):72. PubMed ID: 11993366
[No Abstract] [Full Text] [Related]
10. Who would approve new drugs if there were no FDA?
Gatty B
Hosp Formul; 1995 Jan; 30(1):58, 57. PubMed ID: 10139726
[No Abstract] [Full Text] [Related]
11. Drug information resources for health professionals and consumers.
Durkin C
Natl Netw; 1998 Feb; 22(3):10-1. PubMed ID: 10176590
[No Abstract] [Full Text] [Related]
12. Drug and vaccine development for infectious diseases: the value of priority review vouchers.
Matheny J; Smith B; Courtney B; Mair M
Clin Pharmacol Ther; 2009 Jun; 85(6):571-2. PubMed ID: 19451907
[No Abstract] [Full Text] [Related]
13. Muddied messages about FDA.
Miller HI
Nat Biotechnol; 2003 Jul; 21(7):732-3. PubMed ID: 12833084
[No Abstract] [Full Text] [Related]
14. Requirements for submission of labeling for human prescription drugs and biologics in electronic format. Final rule.
Food and Drug Administration, HHS
Fed Regist; 2003 Dec; 68(238):69009-20. PubMed ID: 14672084
[TBL] [Abstract][Full Text] [Related]
15. Steve Carney talks to Vincent Lee on the pharma industry, the FDA and public education with respect to drugs and their development.
Lee VH
Drug Discov Today; 2005 Nov; 10(21):1411-4. PubMed ID: 16243258
[No Abstract] [Full Text] [Related]
16. Preparing for an FDA preapproval inspection.
Blackmer RA
Qual Assur; 1994 Dec; 3(4):389-403. PubMed ID: 7613749
[TBL] [Abstract][Full Text] [Related]
17. FDA reorganization inspires hope for better coordination.
May M
Nat Med; 2011 Sep; 17(9):1024. PubMed ID: 21900900
[No Abstract] [Full Text] [Related]
18. The big gap at the FDA.
Stipp D
Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178
[No Abstract] [Full Text] [Related]
19. Priority review vouchers: an inefficient and dangerous way to promote neglected-disease drug development.
Kesselheim AS
Clin Pharmacol Ther; 2009 Jun; 85(6):573-5. PubMed ID: 19451908
[No Abstract] [Full Text] [Related]
20. FDA not NIH can speed new drugs.
Miller HI
Nature; 2011 Apr; 472(7342):169. PubMed ID: 21490657
[No Abstract] [Full Text] [Related]
[Next] [New Search]
